TIMOTHY PELLEGRIN: Open Payments
NPI 1134160815 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$64,847 in 185 payments from 17 companies in 2025. Trend: 2023 $46,532 · 2024 $23,015 · 2025 $64,847
Speaker / faculty: $53,905Travel & lodging: $5,289Food & beverage: $3,504Consulting: $2,040Education: $109
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 98 | $58,406 |
| ABBVIE INC. | 18 | $4,947 |
| Alkermes, Inc. | 17 | $230 |
| Teva Pharmaceuticals USA, Inc. | 6 | $222 |
| Janssen Pharmaceuticals, Inc | 4 | $198 |
| Axsome Therapeutics, Inc. | 7 | $152 |
| Vanda Pharmaceuticals Inc. | 8 | $142 |
| Corium, LLC | 7 | $121 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Collegium Pharmaceutical, Inc. | 4 | $73 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, SPRAVATO, Auvelity, FANAPT, Azstarys, REXULTI.
Industry payments across LA — which companies pay providers there.
